Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-05-28FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for COSENTYX (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2021-02-24FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approval of a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc.
-
FDA approval · 2021-01-22FDA Approved: SILIQ — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental Biologics License Application for SILIQ (brodalumab) submitted by Bausch Health US LLC.
-
FDA approval · 2020-12-11FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab filed by Janssen Biotech, Inc. The action updates the product's labeling.
-
FDA approval · 2020-12-01FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approves a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc., reflecting an approval of changes to its label…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-10-16FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for ENSTILAR, a calcipotriene and betamethasone dipropionate combination, from LEO Pharma Inc.
-
FDA approval · 2020-09-02FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' generic calcipotriene and betamethasone dipropionate topical combination for plaque psoriasis.
-
FDA approval · 2020-08-28FDA Approved: CLOBETASOL PROPIONATE CREAM USP, 0.05% CLOBETASOL PROPIONATE CREAM USP, 0.05% — Original Application (Northstar Rx LLC)
FDA approved Northstar Rx LLC's generic clobetasol propionate cream 0.05% (ANDA212982), a potent topical corticosteroid indicated for inflam…
-
FDA approval · 2020-08-27FDA Approved: HALOBETASOL PROPIONATE — Supplemental Application (Coral Way Pharma, LLC)
FDA approved a supplemental application for halobetasol propionate filed by Coral Way Pharma, LLC.
-
FDA approval · 2020-07-20FDA Approved: WYNZORA — Original Application (MC2 Therapeutics Ltd)
FDA approved Wynzora, a fixed-dose combination of calcipotriene and betamethasone dipropionate, under an original NDA by MC2 Therapeutics Lt…
-
FDA approval · 2020-07-06FDA Approved: HULIO — Original Application (Biocon Biologics Inc)
FDA approved HULIO (adalimumab-fkjp) from Biocon Biologics Inc via an original Biologics License Application, a biosimilar to adalimumab. Th…
-
FDA approval · 2020-06-16FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2020-05-29FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) by Eli Lilly and Company. This action pertains to a supplemental filing under…
-
FDA approval · 2020-05-11FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approved Cosette Pharmaceuticals' generic Calcipotriene and Betamethone Dipropionate combination for the treatment of plaque psoriasis.
-
FDA approval · 2020-03-26FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TALTZ (ixekizumab) from Eli Lilly and Company, indicating an updated or expanded indication …
-
FDA approval · 2020-01-27FDA Approved: CLOBETASOL PROPIONATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's generic clobetasol propionate topical product under an original application, expanding access…
-
FDA approval · 2019-12-18FDA Approved: ARAZLO — Original Application (Bausch Health US, LLC)
The FDA approved ARAZLO, a tazarotene topical lotion, under an original application by Bausch Health US, LLC for the treatment of plaque pso…
-
FDA approval · 2019-12-06FDA Approved: AVSOLA — Original Application (Amgen, Inc)
FDA approved AVSOLA (infliximab-axxq) from Amgen as a biosimilar to infliximab, for the same indications as the reference product.
-
FDA approval · 2019-10-21FDA Approved: CLOBETASOL PROPIONATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' original ANDA for clobetasol propionate topical.
-
FDA approval · 2019-10-02FDA Approved: CLOBETASOL PROPIONATE — Original Application (Micro Labs Limited)
The FDA approved Micro Labs Limited's original application for clobetasol propionate topical, a potent corticosteroid, for inflammatory and …
-
FDA approval · 2019-10-02FDA Approved: CLOBETASOL PROPIONATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original application for clobetasol propionate topical, a high-potency corticosteroid, enabli…
-
FDA approval · 2019-09-06FDA Approved: CLOBETASOL PROPIONATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for clobetasol propionate from Sun Pharmaceutical Industries under an ANDA.
-
FDA approval · 2019-09-06FDA Approved: CLOBETASOL PROPIONATE EMOLLIENT FORMULATION — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for a clobetasol propionate emollient formulation from Padagis Israel Pharmaceuticals Ltd, granting …
-
FDA approval · 2019-09-06FDA Approved: CLOBETASOL PROPIONATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for clobetasol propionate from Sun Pharmaceutical Industries, enhancing its approval under the gener…
-
FDA approval · 2019-07-30FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for ENSTILAR (calcipotriene and betamethasone dipropionate) from LEO Pharma Inc.